Physician profile
Michael C Cloud
NPI 1598184970
$9,958.48
in general payments reported to CMS, 2019-2025
48 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $783 · 2021: $1,415 · 2022: $2,034 · 2023: $1,792 · 2024: $1,495 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,334.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,817.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,206.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $867.71 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $702.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $630.38 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $439.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $381.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.85 | 2019-2025 | Xifaxan |
| Dexcom, INC. | $277.55 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $269.28 | 2022-2025 | Rexulti |
| Amgen INC. | $252.16 | 2020-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $227.79 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $197.93 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.15 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $195.30 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.